# Stem cells weekly evidence review - November 9, 2026 Decision: substantive public update warranted. Add FDA manufacturing-quality guidance, a qualified positive knee trial, an exosome eye-safety finding, and newly posted negative primary results for a transplant-complication medicine. Preserve the original deep report and previous updates. Access date: 2026-11-09 PST, verified with the system clock. Previous review: November 2. PubMed entry-date and trial-record update window: November 3-9 inclusive. Publication, indexing, regulatory announcement and result-posting dates are different. This is targeted monitoring, not a systematic review or an exhaustive global approval/license audit. Article: https://managingexpectations.net/blog/articles/stem-cells-evidence-costs-risks-global-guide.html ## Selected evidence and exact scope ### 1. FDA final potency-assurance guidance Official sources: - FDA guidance index, November 2026 entry: https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances - Final guidance landing page: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-potency-assurance-cellular-and-gene-therapy-products - Federal Register notice, November 3, 2026, document 2026-22427, 91 FR 69259-69261, docket FDA-2023-D-4299: https://www.federalregister.gov/documents/2026/11/03/2026-22427/potency-assurance-for-cellular-and-gene-therapy-products-guidance-for-industry-availability - Official printed notice, downloaded and text-extracted: https://www.govinfo.gov/content/pkg/FR-2026-11-03/pdf/2026-22427.pdf The notice finalizes the December 2023 draft. FDA's landing page says it supersedes January 2011 potency-testing guidance. Direct FDA requests hit abuse-detection 404s; alternate extraction recovered the guidance index and landing page. The official GovInfo notice was downloaded successfully. This review does not claim to have downloaded the complete final guidance PDF. Key passage, printed page 69260: potency assurance includes manufacturing process design, manufacturing process control, material control, in-process testing, and potency lot-release assays. Its goal is that each released lot has the ability/capacity to achieve the intended therapeutic effect. The same page states the guidance is not binding on FDA or the public; alternative approaches must satisfy applicable statutes and regulations. A search lead dates the FDA press announcement to November 2, but direct retrieval failed and alternate extraction was rate-limited. Public copy therefore anchors the verified November 3 Federal Register notice, not an asserted first announcement date. This includes catch-up material missed in the previous review. Evidence label: official nonbinding regulatory guidance for section 351 cellular/gene therapy biological products. Not a new product approval, proof of a cure, new blanket law, or exemption for unapproved clinic offerings. Suggested edits: weekly lead and a short addition to the U.S. regulatory row. ### 2. Knee osteoarthritis: positive randomized result with appraisal limits Jaime R. Garza, Claude T. Moorman III, Michael Baria, Daniel Santa Maria, Jay Bowen, Neil Sparks and J. Peter Rubin. "A Single Intra-articular Injection of Autologous Stromal Vascular Fraction for Moderate-to-Severe Knee Osteoarthritis: Results of a Multicenter Randomized Placebo-Controlled Trial With 12-Month Follow-up." American Journal of Sports Medicine, electronic publication November 5, 2026. PMID 42989897; DOI 10.1177/03635465261498163. https://pubmed.ncbi.nlm.nih.gov/42989897/ https://doi.org/10.1177/03635465261498163 Registry: https://clinicaltrials.gov/study/NCT04440189 API: https://clinicaltrials.gov/api/v2/studies/NCT04440189 Official NCBI abstract/XML and registry retrieved. Sage full text returned 403. Abstract-level appraisal only: not a complete audit of adverse-event tables, imaging results, funding or author financial disclosures. The registry identifies GID BIO, Inc. as industry sponsor, triple masking and actual enrollment of 114; its last posted update is April 23, 2025, so recruitment status should not be treated as freshly confirmed. The specific intervention is autologous adipose-derived stromal vascular fraction, a mixed cell preparation, not equivalent to all MSC or cord-cell products. Randomized groups: 83 cell-preparation recipients and 31 placebo recipients. At 12 months, 43/83 (51.8%) versus 9/31 (29.0%) met the paper's composite clinical-response endpoint. Reported difference 22.8 percentage points (95% CI 3.5-42), one-sided p=0.0149. Rates independently checked using Python. Important reporting issue: the abstract describes a composite responder outcome using index and contralateral knees; the retrieved registry describes percent change in WOMAC score as its primary variable. This difference requires the full protocol/statistical analysis plan and record history to reconcile. It is not, by itself, proof of improper outcome switching. Mention the limitation rather than declaring the endpoint fully audited. The abstract says "No serious investigational device-related adverse events were reported." That is not equivalent to no serious adverse events of any cause, nor assurance of long-term or rare-event safety. MRI was collected, but the abstract does not establish cartilage regeneration. One-year symptom improvement does not prove disease modification or durable benefit beyond the study. Evidence label: promising, product-specific randomized human evidence. No new FDA/Health Canada marketing approval established. Retain AAOS caution and do not endorse generic clinic injections. ### 3. Exosome eye trial: observed toxicity, not a broadly safe cell-free cure Ying Tian, Zhuyun Qian, Shuzhen Fan, Jianmin Wang, Wei Wei and Yong Tao. "First-in-Human Regulatory T Cell-Derived Exosomes Plus Ranibizumab for Refractory nAMD." Journal of Extracellular Vesicles, November 5, 2026;15(11):e70396. PMID 42988724; PMCID PMC13739763; DOI 10.1002/jev2.70396. https://pubmed.ncbi.nlm.nih.gov/42988724/ https://pmc.ncbi.nlm.nih.gov/articles/PMC13739763/ Full paper retrieved, especially Abstract, Methods, Results and Discussion. Single centre, open-label phase 1a, four participants, no control group. The product comprised autologous regulatory T-cell-derived exosomes with ranibizumab for refractory wet age-related macular degeneration. These are immune-cell-derived vesicles, not stem cells; included because the report monitors commercial exosome claims. Results section: one participant developed acute sterile intraocular inflammation, marked vision loss and a large intraretinal cyst; the authors report clinical resolution after local treatment. Further escalation stopped. This is an observed dose-limiting toxicity within an experimental combination, not a claim of permanent blindness or proof every exosome product has the same risk. Three participants in the lower-dose cohort completed short-term follow-up without the specified dose-limiting events. Do not infer general safety from three people. All participants also received ranibizumab; visual/anatomic changes cannot be attributed to exosomes alone. Discussion explicitly highlights that limitation, the small sample and absence of controls. Authors declare no conflicts; public research funding and biotechnology-company technical support are acknowledged. Trial identifier reported by authors: ChiCTR2500095798; independent Chinese registry verification not performed. Evidence label: investigational human safety finding. No approval, recommendation, manufacturing instructions, administration schedule or dose is reproduced in the public article or this note. ### 4. Ravulizumab for transplant-associated thrombotic microangiopathy: negative primary comparison ClinicalTrials.gov NCT04543591, "Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant"; sponsor Alexion Pharmaceuticals, Inc. Results first posted November 4, 2026. https://clinicaltrials.gov/study/NCT04543591 https://clinicaltrials.gov/api/v2/studies/NCT04543591 Direct API record and results modules retrieved. Overall enrollment is 148 across stages; the randomized Stage 2 primary analysis comprises 64 and 62 participants (126 total), not all 148. Phase 3, placebo-controlled, masked trial. The primary endpoint is event-free survival through 26 weeks, defined using death or specified clinical worsening. Registry primary analysis: hazard ratio 0.879, 95% CI 0.526-1.467, p=0.6386 (stratified log-rank). Therefore no statistically significant superiority demonstrated. This does not prove equivalence or lack of any possible effect. Stage 2 treatment-period serious adverse events affected 52/63 in the ravulizumab safety population and 44/62 in placebo. Safety denominators differ from randomized efficacy denominators; rescue and follow-up groups must not be added as independent participants. Events are not automatically treatment-caused. Evidence label: sponsor-posted randomized phase 3 results, not a newly peer-reviewed paper or a regulatory decision. Ravulizumab is a medicine tested for a transplant complication, not a stem-cell therapy. The study does not invalidate established transplantation and is not a reason to alter prescribed care. ## Required-source coverage and unchanged conclusions ### FDA - Approved cellular/gene therapy list: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products - Consumer warning: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies - Safety communications index attempted: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications List and consumer page opened through alternate extraction. Indication-specific products include Tregzi, Ryoncil and Casgevy. No new relevant product approval established by this screen. The June 2021 consumer page's historic "only cord blood" footnote must not be used as a current approval inventory. Registration and trial listing do not equal marketing approval. Safety-index retrieval failed both directly (abuse-detection 404) and through alternate extraction (rate limit); do not claim a complete current warning-letter/safety-index check. The independently verified guidance above is the public regulatory addition. ### Health Canada - Autologous policy: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html - Advisory: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Both directly retrieved. The advisory is dated May 15, 2019, not a new warning. Its historical product count is not a current inventory. Targeted current searches first returned older trial listings, then broader searches returned general trial guidance rather than a new cell-specific action. No substantive new Canadian policy/authorization verified. Autologous origin does not establish safety or exemption. Canada row unchanged. ### NIH/NCI, PubMed/PMC and ClinicalTrials.gov - NCI transplant overview: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant - PubMed official search API: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi - Registry API: https://clinicaltrials.gov/api/v2/studies NCI page directly retrieved; established specialist-transplant context retained. PubMed query: (stem cell OR mesenchymal OR iPSC OR exosome OR hematopoietic transplantation) AND (trial OR safety OR adverse OR Parkinson OR diabetes OR spinal cord OR arthritis OR autoimmune OR cancer) AND (2026/11/03:2026/11/09[EDAT]). All 467 returned records retrieved as XML/abstracts. Keyword triage selected 49 records for further screening. Not all 467 were fully appraised; broad matches include unrelated interventions and preclinical work. Registry query: (stem cell OR mesenchymal OR iPSC OR exosome) AND AREA[LastUpdatePostDate]RANGE[2026-11-03,2026-11-09]. All pages collected, 205 records. These are updates, not 205 new cell trials. Newly posted result leads were NCT04543591, NCT04373512 (urinary Lactobacillus after spinal injury, not a stem-cell treatment) and NCT04628494 (epcoritamab versus chemotherapy, not a stem-cell therapy). Only the transplant-complication result above was selected for public addition. Other notable literature: - Ponce et al., Nature Medicine, November 3, PMID 42977758, DOI 10.1038/s41591-026-04686-y: SER-155 microbiome product around allogeneic transplantation. Full publisher text retrieved. Small phase 1b safety study with a secondary bloodstream-infection signal; other secondary outcomes were not significant, industry employment/shareholding disclosed. Not a new stem-cell product, approval or demonstrated survival benefit. Not selected for another public headline. https://pubmed.ncbi.nlm.nih.gov/42977758/ - Chen et al., PMID 42972476, DOI 10.1186/s13287-026-05224-w: 50-patient cord-MSC knee trial, newly indexed in this window but electronic publication August 6. Full PMC retrieved. Small, single-centre study with an active comparator, not a newly published November trial. Kept as catch-up research rather than duplicate knee headline. https://pmc.ncbi.nlm.nih.gov/articles/PMC13729448/ - PMID 42975428: rare-disease OTL-203 hip-imaging follow-up from eight children; secondary uncontrolled analysis with exclusions/missing imaging. Does not establish general orthopedic regeneration. https://pubmed.ncbi.nlm.nih.gov/42975428/ - Diabetes, autoimmune disease, spinal-cord injury and iPSC search matches did not supply a selected, independently verified new broad approval or practice-changing cure claim. Reviews/mechanisms remain distinct from controlled clinical outcomes. ### ISSCR and orthopedic professional guidance - https://www.isscr.org/guidelines - https://www.isscr.org/isscr-news - https://www.isscr.org/public-policy - https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics ISSCR pages retrieved through extraction. Guidelines still identify August 2025 version 1.2, a targeted embryo-model update rather than a new clinical guideline. November 5 poster awards and other organizational notices do not justify changing clinical conclusions. Policy page retains opposition to premature marketing of unproven therapies; its funding advocacy is not clinical evidence. AAOS full page retrieved directly; it continues to emphasize mixed/limited orthopedic evidence, risks and uncertain coverage. New knee findings do not imply AAOS endorsement. ### International policy and medical-tourism checks - EU: https://www.ema.europa.eu/en/news retrieved directly and through extraction. Latest displayed November 6 item concerns veterinary committee business; October human safety/authorization items do not establish a new stem-cell action. Existing European table caveats retained. - UK: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk retrieved. New searches largely repeat the October Casgevy age extension already covered. A November 5 SymBio company-release lead describes preparation for a future brincidofovir application, not authorization: https://www.symbiopharma.com/en/news/pdf/20261105e.pdf . Search-result lead only in this run; not used as verified public evidence. - Japan: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html opened. AMCHEPRY and RiHEART March entries remain; English index still shows Stemirac's original conditional authorization. No final new Stemirac ministry approval verified. A selective translated index cannot certify absence of a Japanese decision. Prior conditional-approval caveats retained. - Singapore: https://www.hsa.gov.sg/announcements/ opened. November 4-6 entries concern adulterated complementary products, vaping enforcement and unrelated drug recalls. No substantive cell-therapy policy change verified. - Australia: https://www.tga.gov.au/news/safety-updates opened. Displayed latest items concern vaccine preparation and GLP-1 safety, not a new cell-therapy warning. This is not an exhaustive ARTG or enforcement audit. - Mexico: targeted COFEPRIS Spanish searches returned older notices, including a December 2015 clinic suspension surrounded by current site-navigation dates. Not relabelled as November 2026 news. https://www.gob.mx/cofepris/prensa/la-cofepris-suspendio-clinica-del-d-f-que-ofrecia-tratamientos-con-celulas-madre-sin-aval-cientifico . Search-level lead only; no new enforcement action verified. - Panama: current searches recirculated the July/August 2026 Stem Cell Reports market critique already checked previously, not a new weekly regulator action. https://www.sciencedirect.com/science/article/pii/S2213671126002286 . No new license or enforcement audit claimed. - Cayman: results dominated by clinic/travel marketing and an older general gazette. No new source-verified rule, comparable pricing change or approval found. Marketing claims of FDA registration are not proof of FDA treatment approval. No clinic endorsement. ### Public outcomes/testimony November 3 Healio report opened: https://www.healio.com/news/neurology/20261103/bemdaneprocel-shows-favorable-safety-profile-over-4-years-in-parkinsons-disease . It describes conference reporting of four-year bemdaneprocel follow-up in 12 Parkinson's patients, including serious adverse events and exploratory motor outcomes. The exact four-year primary poster was not independently retrieved; search found manufacturer-hosted three-year material instead. Retain as reported conference follow-up pending primary-source confirmation, not as a new peer-reviewed efficacy result or anecdotal cure. No new celebrity testimony selected. A nula-cel company/conference story appeared in discovery but was not independently primary-source verified; not promoted into the public report. ## Changes and non-changes Add November 9 subsection after medical caution; advance review date; append the verified FDA guidance to the U.S. regulatory row. Add this source note to sitemap and advance article lastmod to November 9. Keep original deep report and previous updates intact. Leave health.html unchanged: no new report or card added. Prices, images, stylesheet and clinic recommendations unchanged. No dosing, clinic endorsement or medical-tourism recommendation. Local backups: _local-backups/stem-cells-2026-11-09/. Pre-edit article, sitemap and Health page verified byte-identical to Hostinger remote files. DNS resolved to 195.35.15.247; live headers identify Hostinger/LiteSpeed. Remote pre-edit backup: domains/managingexpectations.net/backups/stem-cells-20261109/. Publish only article, this note and sitemap to their directory-specific shared-hosting paths. No KillerWolf or DNS changes. Local-only evidence: research/health/stem-cells-weekly-evidence-2026-11-09/ contains retrieval status, source snapshots, GovInfo PDF, PubMed XML, registry JSON and selected metadata. Raw research can contain treatment protocols and is not deployed. Deployment result belongs in local deploy-verification.json; this source note is not itself a deployment-success claim. Browser-vision tooling unavailable; verify parsed HTML, relative links, remote/live bytes, HTTP status, homepage and existing assets. Top follow-ups: full knee paper and analysis plan to reconcile endpoint wording; controlled longer-term exosome evidence; primary four-year bemdaneprocel poster; new regulator decisions rather than repeated news or clinic marketing. Medical boundary: education and source review only, not medical advice, diagnosis, dosing, treatment guidance or an instruction to seek therapy.